Mount Sinai researchers have developed a rapid blood assay that measures the magnitude and duration of someone’s immunity to SARS-CoV-2, the virus that causes COVID-19. This test will allow large-scale monitoring of the population’s immunity and the effectiveness of current vaccines to help design revaccination strategies for vulnerable immunosuppressed individuals, according to a study published in Nature Biotechnology in June.
“Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule.
Discovery of a metabolic pathways that inhibit memory T cell production has potential for enhancing the immune system’s ability to fight infections and cancers.
St. Jude Children’s Research Hospital has discovered a mechanism that tumors use to switch on protective regulatory T cells, raising the potential for drug treatments that render tumors more vulnerable to cancer immunotherapy.
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
The study demonstrates that T cell activation increases intracellular trafficking via the endoplasmic-reticulum-to-Golgi pathway, and that a protein known as SEC23B — a subunit of the COPII complex — regulates T cells’ production of these important secretory proteins after activation. The work points toward a new potential therapeutic target for decreasing the severity of graft-versus-host-disease (GVHD), a potentially fatal complication of bone marrow transplantation.
in the January 2021 issue, Toxicological Sciences offers an engaging slate of research in toxicology, from endocrine toxicology and biomarkers to genetic and epigenetic toxicology and mixtures toxicology.
Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.
Toxicological Sciences features leading research in toxicology in the areas of biomarkers, environmental toxicology, and more in the September 2020 issue.
It’s clear that radiation therapy, or radiotherapy, an approach used to treat cancer since the early 20th century, can be an effective companion to newer, immune-stimulating approaches known as immunotherapy. Research from a team from Roswell Park Comprehensive Cancer Center explains how radiation helps boost the immune system’s ability to fight cancer in combination with immune checkpoint inhibitors — and provides new evidence that the timing of these therapies can make a big difference in how effectively they work together.
A new study co-led by scientists at the La Jolla Institute for Immunology (LJI) adds increasing evidence that Parkinson’s disease is partly an autoimmune disease. In fact, the researchers report that signs of autoimmunity can appear in Parkinson’s disease patients years before their official diagnosis.
A Ludwig Cancer Research study has discovered a novel means by which bacterial colonies in the small intestine support the generation of regulatory T cells—immune cells that suppress autoimmune reactions and inflammation.
Scientists at St. Jude Children’s Research Hospital mapped the epigenetic controls on T cells, which could aid Type 1 diabetes diagnosis and treatment, as well as cancer immunotherapy.
Dr. Christopher E. Rudd has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours.
Immunologists at St. Jude Children’s Research Hospital have discovered key biological switches that control regulatory T cells—specialized white blood cells that keep the immune system in check.
The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of killer T cells, the foot soldiers of the immune system.
In experiments with mice, UCLA researchers have shown they can harness the power of iNKT cells to attack tumor cells and treat cancer. The new method, described in the journal Cell Stem Cell, suppressed the growth of multiple types of human tumors that had been transplanted into the animals.